Kaigene is a US biotechnology company based in Rockville, Maryland, developing antibody therapeutics for severe autoimmune diseases. Its PDEG platform selectively degrades pathogenic antibodies and suppresses the B cells that produce them, while its NanoBx brain-shuttle technology is aimed at delivering antibodies across the blood-brain barrier for CNS autoimmune indications. Lead asset KG006, a next-generation FcRn inhibitor in IND-enabling development, is licensed to Celltrion for global markets excluding Japan and Greater China and to Taisho Pharmaceutical for Japan.
1
Round
1
Industry
5
Tags
Oct 14, 2026
Latest raise
Funding activity · 1 round
Oct 14, 2026
$55M
Series B
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
